Publications by authors named "Matthew Davids"

Claim this Profile
I
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.
Reid W Merryman, Justin Kline, Robert A Redd, Harrison Olszewski, Emma Welsh, Matthew S Davids

Blood Neoplasia· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
Matthew S Davids, Asher Chanan-Khan, Sikander Ailawadhi, Vladimir Ivanov, Ganna Usenko

Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center.
Kevin H Lin, Lynn Huynh, Xiaoqin Yang, Enrico Zanardo, Daria Liborski, Matthew S Davids

Adv Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma.
Ye Zhang, Lydie Debaize, Adam Langenbucher, Jenalyn Weekes, Ioulia Vogiatzi, Matthew S Davids

Sci Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
Matthew S Davids

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib to assail CLL in the frail.
Christine E Ryan, Matthew S Davids

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.
Lin Wang, Murat Kurt, Tim Disher, Fei Fei Liu, Samantha Craigie, Matthew S Davids

Leuk Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Rapidly Evolving Landscape of the Biology and Therapy of Chronic Lymphocytic Leukemia.
Jennifer R Brown, Matthew S Davids

Hematol Oncol Clin North Am· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triplet Therapies in Chronic Lymphocytic Leukemia.
Jacob D Soumerai, Matthew S Davids

Hematol Oncol Clin North Am· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies.
Stephen J F Chong, Jolin X H Lai, Kartini Iskandar, Benedict J Leong, Chuqi Wang, Matthew S Davids

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor.
Mazyar Shadman, Matthew S Davids

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL.
Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, Christina Papangelou, Evangelia Minga, Matthew S Davids

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of immune escape and extramedullary tropism in leukemia cutis.
Livius Penter, Katie Maurer, Nicoletta Cieri, Wesley Lu, Haoxiang Lyu, Matthew S Davids

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia.
Matthew S Davids, Saad S Kenderian, Ian Flinn, Brian T Hill, Michael Maris

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia.
Kiyomi Mashima, Yanan Kuang, Stacey M Fernandes, Shidong Xu, Benjamin Hanna, Matthew S Davids

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.
Yesid Alvarado-Valero, Rachel J Cook, Shira N Dinner, Michael Keng, Kebede H Begna, Matthew S Davids

Blood Neoplasia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.
Christine E Ryan, Inhye E Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida, Matthew S Davids

Blood Cancer J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
Adam S Kittai, Monia Marchetti, Othman Al-Sawaf, Ohad Benjamini, Alexey V Danilov, Matthew S Davids

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.
Geoffrey Shouse, Canping Chen, Alexandra Muir, Leslie Popplewell, Tanya Siddiqi, Matthew S Davids

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.
James T Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel S Choi, Stacey M Fernandes, Matthew S Davids

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the Management of Relapsed/Refractory CLL and Richter Transformation.
Nathalie Javidi-Sharifi, Matthew S Davids

Hematol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies.
Valentin Jacquier, Andréa Romero, Caroline Molinaro, Ritu Somayaji, Matthieu Abouladze, Matthew S Davids

Theranostics· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma.
Ye Zhang, Lydie Debaize, Adam Langenbucher, Jenalyn Weekes, Ioulia Vogiatzi, Matthew S Davids

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States.
Matthew S Davids, Jacob Ambrose, Enrico de Nigris, Jennifer Prescott, Siyang Leng

Blood Neoplasia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis